


## Leading Digital Health Platform Revolutionizing Physician & Patient Communication

### OPRX Price & Volume



### Key Stats Sources: Nasdaq.com, Company

Stock Price 3/10/21	\$44.61
52 Week Low-High	\$6.50 - \$63.98
Shares Outstanding	16.8M
Public Float est.	96.6%
Market Capitalization	\$750M
Avg. Daily Volume 50-day	257K
Insider Holdings	~3.4%
Institutional Holdings	~65.8%
Employees @12/31/20	73
Revenue ttm	\$43.3M
Net Loss ttm	\$2.2M
Cash <sup>1</sup>	\$81.5M
Debt @12/31/20	\$0
Fiscal Year End	Dec. 31

### Annual Revenue Growth \$millions



### OptimizeRx Contacts

**William Febbo, CEO**

**Doug Baker, CFO**

400 Water Street, Suite 200

Rochester, MI 48307

Tel (248) 651-6568

**Ron Both or Grant Stude, CMA**

Tel (949) 432-7557 OPRX@cma.team

### About OptimizeRx Corporation

- Leading provider of digital health solutions for life science companies, providers and patients.
- Suite of digital and mobile solutions enables patient affordability and adherence.
- Highly leverageable, scalable, low fixed costs operating model, which can generate increasing cash flow as revenues grow.

### Nationwide Digital Health Platform

- Optimize digital health network reaches **695,000+** healthcare providers across the U.S..
- Point of care provider access via 370+ EHRS, and patient engagement via 300+ million mobile devices.
- Clients comprise **world's top 20 pharmaceutical companies** and 60+ other major customers.
- Multiple studies confirm OptimizeRx increases prescription volume with average **ROI of 520%**.

### Recent News Highlights

**Feb. 24:** Q4 2020 revenue up 123% to record \$16.4 million, driving net income of \$1.4 million or \$0.08 per share.

**Feb. 23:** Angelo Campano named to MM+M's 2021 '40 Under 40' list.

**Feb. 9:** Raised \$70.6 million in an equity offering.

**Jan. 25:** Preliminary unaudited results for Q4 2020 revenue up 117% to Record \$1M, full year up 75% to record \$43M.

**Dec. 11:** Recognized as one of the most innovative products for life sciences by PM360 Magazine.

**Dec. 7:** Partnered with Komodo Health to expand life sciences at support point-of-care.


**Dec. 1:** Launched AI-powered real-world evidence solution on point-of-care platform.

### OptimizeRx Digital Health Platform



### Large Market Opportunity

#### Pharma Marketing to Providers<sup>2</sup>



**\$20.3B**

\$4 Billion is Digital

**90%**

U.S. physicians using EHR daily<sup>2</sup>

**5.9 hrs**

Avg. daily EHR use<sup>3</sup>

**500+**

EHRs = fragmentation

**94%**

U.S. consumer mobile phone use<sup>4</sup>

### Electronic Prescribing Adoption

**5 Billion**

eRx Transactions Annually & Growing across hundreds of EHRs used constantly by health care providers<sup>5</sup>

Our Customer

**80%**

Top 50 Pharma Brand

**86%**

Renewal Rate



mrq = most recent quarter and ttm = trailing 12 mo. at 12/31/20. Footnotes: 1) Cash balance includes \$10.5 million as reported on the company's 10-K as of December 31, 2020 and net proceeds of \$71 million from public offering of common stock in February 2021. 2) Globally as of 2016, most recent data available published for first time by JAMA in Jan. 2019; 3) Abstract published on PubMed Sept. 2017. 4) Pew Research Article 2/5/19. 5) SureScripts report; 6) See definition of this non-GAAP term and reconciliation to GAAP in OptimizeRx Corp.'s Q4 and FY 2020 earnings release 2/24/21. **Important Disclaimer:** This document does not constitute an offer to sell, or a solicitation of an offer to buy, any security and may not be relied upon in connection with the purchase or sale of any security. It includes forward looking statements that involves risk and uncertainties as described in OptimizeRx Corp.'s Form 10-K and other reports filed with the SEC and available on www.sec.gov. You should not rely on this document as the basis upon which to make any investment decision. © OptimizeRx Corporation 2020 & 2021. All Rights Reserved. Product of CMA. 031021.